Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma

2007 ◽  
Vol 56 (4) ◽  
pp. 584-587 ◽  
Author(s):  
Jacob A. Sepmeyer ◽  
John P. Greer ◽  
Tatsuki Koyama ◽  
John A. Zic
Keyword(s):  
T Cell ◽  
Pilot Study ◽  
Combination Therapy ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Open Label

scholarly journals 293 Rational design of combination therapy in cutaneous T-cell lymphoma using an HDAC inhibitor and alkylating agent

2017 ◽  
Vol 137 (5) ◽  
pp. S50
Author(s):  
C. Patrone ◽  
M. Sanchez-Martin ◽  
M. Frattini ◽  
A. Ferrando ◽  
T. Palomero ◽  
...  
Keyword(s):  
T Cell ◽  
Combination Therapy ◽  
Hdac Inhibitor ◽  
Rational Design ◽  
Alkylating Agent ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma

Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma

2007 ◽  
Vol 25 (21) ◽  
pp. 3109-3115 ◽  
Author(s):  
Elise A. Olsen ◽  
Youn H. Kim ◽  
Timothy M. Kuzel ◽  
Theresa R. Pacheco ◽  
Francine M. Foss ◽  
...  
Keyword(s):  
T Cell ◽  
Assessment Tool ◽  
Cell Lymphoma ◽  
Objective Response ◽  
Multicenter Trial ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Open Label ◽  
Open Label Phase ◽  
Treatment Refractory

PurposeTo evaluate the activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in persistent, progressive, or recurrent mycosis fungoides or Sézary syndrome (MF/SS) cutaneous t-cell lymphoma (CTCL) subtypes.Patients and MethodsPatients with stage IB-IVA MF/SS were treated with 400 mg of oral vorinostat daily until disease progression or intolerable toxicity in this open-label phase IIb trial ( NCT00091559 ). Patients must have received at least two prior systemic therapies at least one of which included bexarotene unless intolerable. The primary end point was the objective response rate (ORR) measured by the modified severity weighted assessment tool and secondary end points were time to response (TTR), time to progression (TTP), duration of response (DOR), and pruritus relief (≥ 3-point improvement on a 10-point visual analog scale). Safety and tolerability were also evaluated.ResultsSeventy-four patients were enrolled, including 61 with at least stage IIB disease. The ORR was 29.7% overall; 29.5% in stage IIB or higher patients. Median TTR in stage IIB or higher patients was 56 days. Median DOR was not reached but estimated to be ≥ 185 days (34+ to 441+). Median TTP was 4.9 months overall, and ≥ 9.8 months for stage IIB or higher responders. Overall, 32% of patients had pruritus relief. The most common drug-related adverse experiences (AE) were diarrhea (49%), fatigue (46%), nausea (43%), and anorexia (26%); most were grade 2 or lower but those grade 3 or higher included fatigue (5%), pulmonary embolism (5%), thrombocytopenia (5%), and nausea (4%). Eleven patients required dose modification and nine discontinued due to AE.ConclusionOral vorinostat was effective in treatment refractory MF/SS with an acceptable safety profile.

Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma

2016 ◽  
Vol 20 (3) ◽  
pp. 244-248 ◽  
Author(s):  
Catherine Besner Morin ◽  
David Roberge ◽  
Irina Turchin ◽  
Tina Petrogiannis-Haliotis ◽  
Gizelle Popradi ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Early Stage ◽  
Complete Response ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Open Label ◽  
Topical Retinoids ◽  
Few Data ◽  
Mean Time

Background: Numerous treatments are available for cutaneous T-cell lymphoma (CTCL), including systemic retinoids. Very few data are available on topical retinoids. Objectives: The aim of this study was to evaluate the safety and efficiency of tazarotene as monotherapy for early-stage CTCL. Methods: An open-label, prospective study of tazarotene as monotherapy for stages IA to IIA CTCL was conducted. Index lesions on 10 patients were followed for 6 months on treatment, plus at least 6 months off treatment. Results: Six patients (60%) showed complete response (CR). Erythema, scaling, thickness, and lesion area decreased progressively throughout treatment. The mean time to CR was 3.8 months; CR was durable for at least 6 months in 83%. Of the 4 patients (40%) without CR, 2 (20%) had stable disease and 2 (20%) stopped the medication because of local side effects; none showed progression. Conclusions: This is the first Canadian trial providing evidence that topical tazarotene has excellent potential as a monotherapy agent for stages I to IIA CTCL.

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

The Lancet ◽  
2017 ◽  
Vol 390 (10094) ◽  
pp. 555-566 ◽  
Author(s):  
H Miles Prince ◽  
Youn H Kim ◽  
Steven M Horwitz ◽  
Reinhard Dummer ◽  
Julia Scarisbrick ◽  
...  
Keyword(s):  
T Cell ◽  
Multicentre Trial ◽  
Cell Lymphoma ◽  
Brentuximab Vedotin ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Open Label ◽  
Phase 3

scholarly journals Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma

2014 ◽  
Vol 167 (1) ◽  
pp. 141-144 ◽  
Author(s):  
Juliet Fraser Gibson ◽  
Francine Foss ◽  
Dennis Cooper ◽  
Stuart Seropian ◽  
Diana Irizarry ◽  
...  
Keyword(s):  
T Cell ◽  
Pilot Study ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma

A multicenter, open label, phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e20044-e20044
Author(s):  
Simone M. Goldinger ◽  
Sharon Gobbi ◽  
Michelle Ding ◽  
Anna Lisa Frauchiger ◽  
Regina Fink-Puches ◽  
...  
Keyword(s):  
T Cell ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Efficacy And Safety ◽  
Open Label ◽  
Open Label Phase

scholarly journals Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

2018 ◽  
Vol 19 (9) ◽  
pp. 1192-1204 ◽  
Author(s):  
Youn H Kim ◽  
Martine Bagot ◽  
Lauren Pinter-Brown ◽  
Alain H Rook ◽  
Pierluigi Porcu ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Open Label ◽  
Phase 3 ◽  
Previously Treated ◽  
Randomised Controlled
Sign in / Sign up

Export Citation Format

Share Document